Summary & Overview
HCPCS Level II A9180: Pediculosis Topical Treatment for Patient/Caretaker
HCPCS Level II code A9180 identifies topical treatments for pediculosis (lice infestation) intended for administration by the patient or a caregiver. This code is used when medication is supplied for home use rather than applied by a clinician, and it matters nationally because pediculosis is a common condition across pediatric and adult populations that often requires outpatient, community, or home-based management. Accurate coding affects coverage determination, pharmacy dispensing, and claims processing for these commonly used topical agents.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for the code, expected sites of service, typical billing considerations, and the types of benchmarks and policy issues that influence coverage and claims adjudication for self-administered topical lice treatments. The publication outlines common modifiers and payer patterns where available, notes areas where inputs were not provided, and situates the code within broader outpatient and pharmacy-managed care workflows. This summary is intended to help billing managers, revenue integrity teams, and policy analysts understand the functional role of A9180 in claims and benefit design at a national level.
Billing Code Overview
HCPCS Level II code A9180 denotes pediculosis (lice infestation) treatment, topical, for administration by patient/caretaker. This item represents topical anti-parasitic medication intended to be applied by the patient or a caregiver rather than administered in a clinical setting.
Service Type: Topical pharmacologic treatment provided for self- or caretaker-administration.
Typical Site of Service: Home or community setting (self-care by patient or caretaker).
Clinical & Coding Specifications
Clinical Context
A school-aged child presents to a primary care clinic with intense scalp itching and visible nits and live lice on examination. The clinician confirms pediculosis capitis and prescribes an over-the-counter or prescription topical pediculicide for administration by the parent/caregiver at home. The workflow includes diagnosis and documentation of lice infestation, counseling on proper application of the topical agent, demonstration or provision of written instructions for caregiver-administered treatment, and scheduling any necessary return or follow-up (for example, reevaluation in 7–10 days). The topical product is supplied or dispensed to the patient/caregiver at the clinic or written as a prescription for pharmacy pickup; billing for the topical pediculosis treatment intended for self/caregiver administration is submitted under A9180. Typical sites of service are outpatient primary care offices, pediatric clinics, school-based health centers, urgent care centers, and community health clinics. Care documentation includes diagnosis code(s), documentation of counseling and instructions provided to caregiver, quantity dispensed, and product name/strength when applicable.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard billing | Use when no special circumstance applies and service is billed as usual. |